Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 08 2019
Historique:
received: 19 11 2018
revised: 27 04 2019
accepted: 07 06 2019
pubmed: 14 6 2019
medline: 16 4 2020
entrez: 14 6 2019
Statut: ppublish

Résumé

Cancer cell-intrinsic properties caused by oncogenic mutations have been well characterized; however, how specific oncogenes and tumor suppressors impact the tumor microenvironment (TME) is not well understood. Here, we present a novel non-cell-autonomous function of the retinoblastoma (RB) tumor suppressor in controlling the TME. RB inactivation stimulated tumor growth and neoangiogenesis in a syngeneic and orthotropic murine soft-tissue sarcoma model, which was associated with recruitment of tumor-associated macrophages (TAM) and immunosuppressive cells such as Gr1

Identifiants

pubmed: 31189648
pii: 0008-5472.CAN-18-3604
doi: 10.1158/0008-5472.CAN-18-3604
doi:

Substances chimiques

CCL2 protein, human 0
CCR2 protein, human 0
Ccl2 protein, mouse 0
Ccr2 protein, mouse 0
Chemokine CCL2 0
Receptors, CCR2 0
Retinoblastoma Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3903-3915

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Fengkai Li (F)

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

Shunsuke Kitajima (S)

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan. chtakaha@staff.kanazawa-u.ac.jp shunsuke_kitajima@dfci.harvard.edu.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Susumu Kohno (S)

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

Akiyo Yoshida (A)

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.
Keiju Medical Center, Nanao, Ishikawa, Japan.

Shoichiro Tange (S)

Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University, Sapporo, Japan.

Soichiro Sasaki (S)

Division of Molecular Bioregulation, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

Nobuhiro Okada (N)

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.
Department of Nano-Biotechnology, Graduate School of Interdisciplinary Science & Engineering in Health Systems, Okayama University, Okayama, Okayama, Japan.

Yuuki Nishimoto (Y)

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

Hayato Muranaka (H)

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

Naoko Nagatani (N)

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

Misa Suzuki (M)

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

Sayuri Masuda (S)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Tran C Thai (TC)

Keiju Medical Center, Nanao, Ishikawa, Japan.

Takumi Nishiuchi (T)

Division of Functional Genomics, Advanced Science Research Center, Kanazawa University, Kanazawa, Ishikawa, Japan.

Tomoaki Tanaka (T)

Department of Molecular Diagnosis, Chiba University Graduate School of Medicine, Chiba, Japan.

David A Barbie (DA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Naofumi Mukaida (N)

Division of Molecular Bioregulation, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

Chiaki Takahashi (C)

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan. chtakaha@staff.kanazawa-u.ac.jp shunsuke_kitajima@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH